Claims for Patent: 8,609,670

Summary for Patent: 8,609,670

Title:	Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
Abstract:	The invention relates to novel piperidino-dihydrothienopyrimidine sulfoxides of formula I,
Inventor(s):	Pascale A. J. Pouzet, Peter Nickolaus, Ulrike Werthmann, Rogelio Perez Frutos, Bing-Shiou Yang, Soojin Kim, Jason Alan Mulder, Nitinchandra D. Patel, Chris Hugh Sananayake, Thomas Gabriel Tampone, Xudong Wei
Assignee:	Boehringer Ingelheim International GmbH
Application Number:	US13/592,664
Patent Claims:	1. A compound of formula I wherein: Ring A is phenyl, pyridinyl, or pyrimidinyl, R is Cl and is located in the para-, meta-, or ortho-position of Ring A, and S* is a sulphur atom that represents a chiral center, or a pharmaceutically acceptable salt thereof. 2. The compound of formula I according to claim 1, wherein R is in the para-position of Ring A, or a pharmaceutically acceptable salt thereof. 3. The compound according to claim 1, which is a compound of formula II or a pharmaceutically acceptable salt thereof. 4. The compound according to claim 1, which is a compound of formula III or a pharmaceutically acceptable salt thereof. 5. The compound according to claim 1, wherein S* is in the R-configuration. 6. The compound according to claim 1, wherein S* is in the S-configuration. 7. A crystalline anhydrous compound of formula III according to claim 4, which shows a reflex peak in the X-ray powder diffraction diagram with a d-value of 4.62 Å. 8. A crystalline anhydrous compound of formula III according to claim 4, which shows reflex peaks in the X-ray powder diffraction diagram with d-values of 4.62 Å, 6.82 Å, and 10.09 Å. 9. A crystalline anhydrous compound of formula III according to claim 4, which shows reflex peaks in the X-ray powder diffraction diagram with d-values of 4.62 Å, 4.17 Å, and 3.66 Å. 10. A crystalline anhydrous compound of formula III according to claim 4, which shows reflex peaks in the X-ray powder diffraction diagram with d-values of 4.62 Å, 6.82 Å, 10.09 Å, 3.93 Å, and 4.94 Å. 11. A crystalline anhydrous compound of formula III according to claim 4, which shows reflex peaks in the X-ray powder diffraction diagram with d-values of 4.62 Å, 4.17 Å, 3.66 Å, 3.73 Å, and 18.47 Å. 12. A crystalline dihydrate compound of formula III according to claim 4, which shows a reflex peak in the X-ray powder diffraction diagram with a d-value of 4.12 Å. 13. A crystalline dihydrate compound of formula III according to claim 4, which shows reflex peaks in the X-ray powder diffraction diagram with d-values of 4.12 Å, 4.29 Å, and 5.15 Å. 14. A crystalline dihydrate compound of formula III according to claim 4, which shows reflex peaks in the X-ray powder diffraction diagram with d-values of 4.12 Å, 4.29 Å, 5.15 Å, 3.95 Å, and 3.36 Å. 15. The compound of formula I according to claim 1, wherein Ring A is phenyl, or a pharmaceutically acceptable salt thereof. 16. The compound of formula I according to claim 1, wherein Ring A is pyridinyl, or a pharmaceutically acceptable salt thereof. 17. The compound of formula I according to claim 1, wherein Ring A is pyrimidinyl, or a pharmaceutically acceptable salt thereof. 18. The compound according to claim 3, wherein S* is in the R-configuration. 19. The compound according to claim 3, wherein S* is in the S-configuration. 20. The compound according to claim 4, wherein S* is in the R-configuration. 21. The compound according to claim 4, wherein S* is in the S-configuration. 22. A racemate of the compound according to claim 1. 23. A pharmaceutical composition comprising a compound of formula I according to claim 1 and an active substance selected from the group consisting of betamimetics, corticosteroids, anticholinergics, other PDE4 inhibitors, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, MRP4-inhibitors, and SYK inhibitors. 24. A pharmaceutical composition comprising a compound of formula I according to claim 5 and an active substance selected from the group consisting of betamimetics, corticosteroids, anticholinergics, other PDE4 inhibitors, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, MRP4-inhibitors, and SYK inhibitors. 25. A pharmaceutical composition comprising a compound of formula I according to claim 6 and an active substance selected from the group consisting of betamimetics, corticosteroids, anticholinergics, other PDE4 inhibitors, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, MRP4-inhibitors, and SYK inhibitors. 26. A pharmaceutical composition comprising a compound of formula I according to claim 15 and an active substance selected from the group consisting of betamimetics, corticosteroids, anticholinergics, other PDE4 inhibitors, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, MRP4-inhibitors, and SYK inhibitors. 27. A pharmaceutical composition comprising a compound of formula I according to claim 16 and an active substance selected from the group consisting of betamimetics, corticosteroids, anticholinergics, other PDE4 inhibitors, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, MRP4-inhibitors, and SYK inhibitors. 28. A pharmaceutical composition comprising a compound of formula I according to claim 17 and an active substance selected from the group consisting of betamimetics, corticosteroids, anticholinergics, other PDE4 inhibitors, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, MRP4-inhibitors, and SYK inhibitors. 29. A pharmaceutical composition comprising a compound of formula II according to claim 18 and an active substance selected from the group consisting of betamimetics, corticosteroids, anticholinergics, other PDE4 inhibitors, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, MRP4-inhibitors, and SYK inhibitors. 30. A pharmaceutical composition comprising a compound of formula II according to claim 19 and an active substance selected from the group consisting of betamimetics, corticosteroids, anticholinergics, other PDE4 inhibitors, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, MRP4-inhibitors, and SYK inhibitors. 31. A pharmaceutical composition comprising a compound of formula III according to claim 4 and an active substance selected from the group consisting of betamimetics, corticosteroids, anticholinergics, other PDE4 inhibitors, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, MRP4-inhibitors, and SYK inhibitors. 32. A pharmaceutical composition comprising a compound of formula III according to claim 20 and an active substance selected from the group consisting of betamimetics, corticosteroids, anticholinergics, other PDE4 inhibitors, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, MRP4-inhibitors, and SYK inhibitors. 33. A pharmaceutical composition comprising a compound of formula III according to claim 21 and an active substance selected from the group consisting of betamimetics, corticosteroids, anticholinergics, other PDE4 inhibitors, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, MRP4-inhibitors, and SYK inhibitors. 34. A pharmaceutical composition comprising a racemate according to claim 22 and an active substance selected from the group consisting of betamimetics, corticosteroids, anticholinergics, other PDE4 inhibitors, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, MRP4-inhibitors, and SYK inhibitors.